NASDAQ:ROIV Roivant Sciences (ROIV) Stock Forecast, Price & News $12.55 -0.64 (-4.85%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$12.25▼$13.2450-Day Range$10.21▼$13.1952-Week Range$3.14▼$13.24Volume8.27 million shsAverage Volume6.12 million shsMarket Capitalization$9.69 billionP/E RatioN/ADividend YieldN/APrice Target$15.38 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Roivant Sciences MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside22.5% Upside$15.38 Price TargetShort InterestHealthy3.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 14 Articles This WeekInsider TradingSelling Shares$8.32 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.06) to ($1.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.87 out of 5 starsMedical Sector746th out of 970 stocksPharmaceutical Preparations Industry356th out of 454 stocks 2.4 Analyst's Opinion Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.38, Roivant Sciences has a forecasted upside of 22.5% from its current price of $12.55.Amount of Analyst CoverageRoivant Sciences has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.64% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Roivant Sciences has recently decreased by 13.45%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ROIV. Previous Next 2.0 News and Social Media Coverage News SentimentRoivant Sciences has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Roivant Sciences this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for ROIV on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,323,241.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Roivant Sciences are expected to decrease in the coming year, from ($1.06) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is -9.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is -9.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 5.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Roivant Sciences (NASDAQ:ROIV) StockRoivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Read More ROIV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ROIV Stock News HeadlinesSeptember 28, 2023 | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) Hits New 1-Year High on Analyst UpgradeSeptember 27, 2023 | msn.comGoldman Sachs Maintains Roivant Sciences (ROIV) Buy RecommendationSeptember 29, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 27, 2023 | americanbankingnews.comRoivant Sciences' (ROIV) "Buy" Rating Reiterated at Truist FinancialSeptember 27, 2023 | americanbankingnews.comRoivant Sciences Target of Unusually Large Options Trading (NASDAQ:ROIV)September 26, 2023 | markets.businessinsider.comBuy Rating for Roivant Sciences: Positive Drug Trials and Promising Future DevelopmentsSeptember 26, 2023 | in.investing.comVivek Ramaswamy's Roivant jumps 19% on positive IMVT trial dataSeptember 26, 2023 | barrons.comS&P 500 Futures Decline in Premarket Trading; Roivant Sciences, Liberty Media SiriusXM A LeadSeptember 29, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 19, 2023 | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) Given Overweight Rating at Cantor FitzgeraldSeptember 18, 2023 | msn.comVivek Ramaswamy's ex-employees say he's a "neurotic, paranoid" bossSeptember 17, 2023 | msn.comWhite House aspirant Vivek Ramaswamy vows to end H-1B visa programme, calls it 'indentured servitude'September 17, 2023 | msn.comUS Presidential Aspirant Vivek Ramaswamy Vows To End H-1B Visa Programme, Calls It 'Indentured Servitude'September 16, 2023 | msn.comVivek Ramaswamy a 'paranoid leader', accused of treating employees like servantsSeptember 16, 2023 | msn.comVivek Ramaswamy's Bid: Paranoid President in the Making?September 16, 2023 | msn.comVivek Ramaswamy a 'paranoid' leader, treated employees like servants: ReportSeptember 15, 2023 | msn.comVivek Ramaswamy demands office temperature be set at 64 degrees or lower: ‘Likes it chilly’September 13, 2023 | benzinga.comRoivant Sciences Chief Operating Officer Acquires 106,430 Shares After Exercising Company Stock OptionsSeptember 11, 2023 | seekingalpha.comSkin In The Game: Behind Roivant's Significant RiseSeptember 9, 2023 | finance.yahoo.comThe Brash Strategy That Made Vivek Ramaswamy a FortuneSeptember 6, 2023 | msn.comWho is GOP presidential candidate Vivek Ramaswamy?September 5, 2023 | barrons.comS&P 500 Futures Fall in Premarket Trading; VinFast Auto, Roivant Sciences LagSeptember 5, 2023 | msn.comWhat Vivek Ramaswamy Surprisingly Has In Common With Warren BuffettSeptember 3, 2023 | ft.comVivek Ramaswamy’s FDA ‘corruption’ claims disavowed by RoivantSeptember 2, 2023 | news.yahoo.comVivek Ramaswamy is not the presidential candidate that young people were hoping for | OpinionSeptember 2, 2023 | fool.comRoivant Sciences (NASDAQ: ROIV)September 1, 2023 | msn.comCantor Fitzgerald Reiterates Roivant Sciences (ROIV) Overweight RecommendationSee More Headlines Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ROIV Company Calendar Last Earnings8/14/2023Today9/29/2023Next Earnings (Estimated)11/13/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ROIV CUSIPN/A CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees904Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.38 High Stock Price Forecast$23.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+22.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,009,030,000.00 Net Margins-1,233.11% Pretax Margin-1,528.46% Return on Equity-73.68% Return on Assets-48.46% Debt Debt-to-Equity Ratio0.29 Current Ratio6.37 Quick Ratio6.37 Sales & Book Value Annual Sales$61.28 million Price / Sales158.05 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book5.95Miscellaneous Outstanding Shares771,740,000Free Float736,242,000Market Cap$9.69 billion OptionableNot Optionable Beta1.28 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Matthew Gline (Age 39)CEO & Director Comp: $1.77MDr. Eric Venker M.D. (Age 36)Pharm.D., Pres & COO Comp: $1.28MDr. Mayukh Sukhatme M.D. (Age 47)Pres & Chief Investment Officer Comp: $1.72MMr. Richard Pulik (Age 43)Chief Financial Officer Ms. Rakhi Kumar (Age 43)Chief Accounting Officer Dr. Huafeng Xu Ph.D.Chief Technology OfficerMr. Josh ChenGen. CounselMs. Kelly GraffHead of PeopleMs. Marianne L. Romeo (Age 55)Head of Global Transactions & Risk Management Mr. Alex GasnerExec. VP of Roivant HealthMore ExecutivesKey CompetitorsVerona PharmaNASDAQ:VRNASarepta TherapeuticsNASDAQ:SRPTLegend BiotechNASDAQ:LEGNJazz PharmaceuticalsNASDAQ:JAZZUnited TherapeuticsNASDAQ:UTHRView All CompetitorsInsiders & InstitutionsDavidson Kempner Capital Management LPBought 1,300,000 shares on 9/12/2023Ownership: 0.000%Eric VenkerSold 106,430 sharesTotal: $1.30 M ($12.19/share)Rakhi KumarSold 99,350 sharesTotal: $1.21 M ($12.18/share)Eric VenkerSold 5,926 sharesTotal: $70,223.10 ($11.85/share)Rakhi KumarSold 1,724 sharesTotal: $20,688.00 ($12.00/share)View All Insider TransactionsView All Institutional Transactions ROIV Stock - Frequently Asked Questions Should I buy or sell Roivant Sciences stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ROIV shares. View ROIV analyst ratings or view top-rated stocks. What is Roivant Sciences' stock price forecast for 2023? 8 brokerages have issued 12 month target prices for Roivant Sciences' shares. Their ROIV share price forecasts range from $10.00 to $23.00. On average, they predict the company's share price to reach $15.38 in the next year. This suggests a possible upside of 22.5% from the stock's current price. View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts. How have ROIV shares performed in 2023? Roivant Sciences' stock was trading at $7.99 on January 1st, 2023. Since then, ROIV stock has increased by 57.1% and is now trading at $12.55. View the best growth stocks for 2023 here. Are investors shorting Roivant Sciences? Roivant Sciences saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 18,340,000 shares, a decrease of 13.4% from the August 31st total of 21,190,000 shares. Based on an average daily volume of 4,980,000 shares, the short-interest ratio is presently 3.7 days. Currently, 3.6% of the shares of the stock are sold short. View Roivant Sciences' Short Interest. When is Roivant Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ROIV earnings forecast. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.10. The firm earned $21.60 million during the quarter, compared to the consensus estimate of $24.49 million. Roivant Sciences had a negative net margin of 1,233.11% and a negative trailing twelve-month return on equity of 73.68%. The company's revenue was up 402.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.48) earnings per share. What ETFs hold Roivant Sciences' stock? ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Moonshot Innovators ETF (MOON), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3X Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), Invesco Dorsey Wright Momentum ETF (PDP) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What is Roivant Sciences' stock symbol? Roivant Sciences trades on the NASDAQ under the ticker symbol "ROIV." How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Roivant Sciences' stock price today? One share of ROIV stock can currently be purchased for approximately $12.55. How much money does Roivant Sciences make? Roivant Sciences (NASDAQ:ROIV) has a market capitalization of $9.69 billion and generates $61.28 million in revenue each year. The company earns $-1,009,030,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. How many employees does Roivant Sciences have? The company employs 904 workers across the globe. How can I contact Roivant Sciences? Roivant Sciences' mailing address is Clarendon House, 2 Church Street, Hamilton Parish HM 11. The official website for the company is roivant.com. The company can be reached via phone at 44-20-7400-3347. This page (NASDAQ:ROIV) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.